**Venue: Prescrire’s meeting rooms, 68-70 Boulevard Richard Lenoir, 75011 Paris**

**HOW CAN WE PREVENT THAT DRUGS DO MORE HARM THAN GOOD…**

**AGENDA**

|  |  |
| --- | --- |
| **Thursday, 10 October 2019 - morning** | |
| 9:00-10:00 | Registration for members – Meet together and coffee & tea |
| 10:00-12:30 | ISDB internal affairs  Welcome by ISDB President and Prescrire (Pierre Chirac)   * Call for new committee candidates * Financial matters: accounting report, membership subscription status (Luis Carlos Saiz Fernadez, ISDB Treasurer) * Membership: update on new and no-longer-members, presentation of new members * Report from the ISDB Committee on main activities since 2016 * Review of bulletin quality (Maria Font, Infofarma, Italy) * Update on implementation of new ISDB conflict of interest policy (Dick Bijl) * ISDB website update (Dick Bijl) * Clinical trials working group (Nuria Homedes, USA) * HTA - advocacy group (Rita Kessler, Prescrire, France) * Barbara Mintzes (University of Sydney) Comparison of post-market safety warnings of FDA, MHRA/EMA, Health Canada and TGA   **Moderator:** Dick Bijl (ISDB President) |
| 12:30-14:00 | Registration for non-members – Lunch on the spot |

|  |  |
| --- | --- |
| **Thursday, 10 October 2019 - afternoon** | |
| 14:00-15:30 | Drug regulatory environment, quality of the evidence needed  **Introduction:** Dick Bijl (ISDB President) talking about the challenge  **Speakers:**   * **Jordi Llinares** (Head or Scientific and Regulatory Management at the European Medicines Agency, EMA): *Presubmission contacts with marketing authorisation applicants and Priority Medicines scheme (PRIME).* * **Claudia Wild** (Director of Ludwig Bolzmann Institute for HTA, Austria): *Oncologic drugs: little evidence about clinical benefits at time of approval, what is known shows marginal effectiveness of most drugs.* * **Sidney Wolfe** (Worst Pills – Best Pills, USA): *Breaking through Corporate/Government Duopoly of Power*   **Discussion:** ISDB members’ experience and recommendations – What kind of evidence ISDB members want from regulators?  **Moderator:** Christophe Kopp (Prescrire, France) |
| 15:30-16:00 | Coffee & tea break |
| 16:00-17:30 | *Andrew Herxheimer Memorial Session:* Evidence-based deprescribing: a challenge for independent drug bulletins  **Speakers:**   * **Alan Cassels** (Therapeutics Initiative, Canada) * **Dee Mangin** (TaperMD, Canada) * **Anne Sophie Parent** (AGE platform, Europe)   **Discussion**  **Moderator:** Thierry Christiaens (Folia Pharmacotherapeutica, Belgium) |
| 19:00 | Dinner at Molly’s 91 rue de Charenton |

|  |  |
| --- | --- |
| Friday, 11 October 2019 - morning | |
| 9:00 -10:30 | Conflicts of interest (CoI) and elaboration of trusted evidence:  the way forward  *The Cochrane affair and other CoI issues: lessons and consequences for ISDB bulletins*  **Speakers:**   * **Zoé Friedmann** (Universities Allied for Essential Medicines, UAEM Germany): *CoI and medical students* * **Juan Erviti** (Cochrane Hypertension Group, DTB Navarre) * **Peter Gøtzsche** (Institute for Scientific Freedom, Denmark)   **Discussion**  **Moderator:** Jörg Schaaber (Pharma-Brief, Germany) |
| 10:30 -11:00 | Coffee & tea break |
| 11:00 -12:30 | How to deal with Big Data? Pros and Cons  **Speakers:**   * **Gerd Antes** (Ex Director, Cochrane Germany): *Big Data – marketing driven hype versus science based progress, where are we going?* * **Rita Banzi** (Head of the Center for Health Regulatory Policies – Mario Negri Institute, Italy): *Real world data for regulatory decisions*   **Discussion**  **Moderator:** Rita Kessler (Prescrire, France) |
| 12:30 -14:00 | Lunch |

|  |  |
| --- | --- |
| Friday, 11 October 2019 - afternoon | |
| 14:00 -16:00 | Pharmacovigilance and lessons from health scandals  **Speakers:**   * **Juan Laporte** (Fundació Institut Català de Farmacologia - Founder and director of Butlletí Groc since 1984) * **David Healy** (RxISK - Bangor University (UK) * **Adriane Fugh-Berman** (Georgetown University, Washington DC/ PharmedOut) opioid crisis USA * **Marine Martin** (President of Association of Parents of Children with Anticonvulsant Syndrome - APESAC France)   **Discussion**  **Moderator:** Maria Font (Infofarma, Italy) |
| 16:00-16:30 | Coffee & tea break and walking around the posters |
| 16:30-18:00 | Drug Information in the news and new media: a challenge for Independent quality drug information  **Speakers:**   * Alan Cassels (Therapeutics Initiative, Canada): *Is the media a reliable source of drug information?* * Anna Coretchi (Medex-Corsum, Moldova): *Use of new channels for independent quality drug information*   **Discussion**  Moderator: Barbara Mintzes (University of Sydney, Australia) |

|  |  |
| --- | --- |
| Saturday, 12 October 2019 | |
| 9:00-10:00 | Drug market in the global South: a challenge for ISDB  **Speakers:**   * Martín Cañas (Argentina), editor of Folia Doc, Medical Federation of Buenos Aires Province bulletin, co-founder of the Latin America and Caribbean Drug information centers Network * Carlos Duran (Excellencis Ecuador), editor of the Ecuadorian Therapeutic Formulary * Gopal Dabade (SANJEEVINI bulletin, India), cofounder and president of Drug Action Forum – Karnataka (DAF-K), member of All India Drug Action Network (AIDAN)   **Discussion**  **Moderator:** Benito Marchand (Excellencis Ecuador) |
| 10:00-10:30 | Coffee & tea break |
| 10:30-12:00 | ISDB internal affairs   * ISDB on the map: news from the regions * Canada: 25 years Therapeutics Initiative * EU: new EU Commission and Parliament: perspectives, working with other organisations * Other regions * Results from meeting and discussion of ISDB priorities and work programme * Election of new Committee * Closure of the meeting |
| 12:00-14:00 | Lunch and Meeting of the new Committee |
| 14:30 | End of General Assembly |